Cancer Genetics Expands BioDiscovery's Nexus Copy Number Platform to Identify Novel Biomarkers Predictive of Cancer Outcomes
Hawthorne, CA and Rutherford, NJ (PRWEB) April 02, 2014 -- Cancer Genetics, Inc. (Nasdaq: CGIX) and BioDiscovery, Inc. have announced expansion of the Nexus Copy Number Discovery platform in CGI research to uncover novel biomarkers which are predictive of cancer outcomes.
“Cancer Genetics has been able to leverage the Nexus Copy Number platform’s unique ability to quickly digest large data sets to uncover correlations between genomic events and clinical factors in their discovery efforts,” says Louis J. Culot, Vice President of Business Development and Marketing at BioDiscovery. “Cancer Genetics is an emerging leader in DNA cancer diagnostics. We are excited about the opportunity to play a role in the work being done and the impact that work is having on improving patient outcomes.”
“The Nexus Copy Number product is one of the primary analytic and collaboration tools for CGI’s R&D platform” says Jane Houldsworth, PhD, Vice President of Research and Development at CGI, “allowing our scientists to quickly mine complex data sets for underlying diagnostic and prognostic markers.” CGI expects to utilize the many new features in Nexus Copy Number version 7.5, such as the ability to automatically classify samples with particular genomic aberrations, and plans to take advantage of the NGS support in the updated version. According to CGI, the team at BioDiscovery has been highly responsive to scientists’ needs, accelerating research and development.
BioDiscovery Nexus Copy Number software offers simple yet powerful tools for copy number and sequence variation (CNV) analysis and visualization from microarrays and next generation sequencing (NGS), for analysis of complex data such as solid tumor samples and complex constitutional disease. The scientist-driven software embeds powerful statistical tools designed specifically for the end-user, allowing rapid detection of chromosomal aberrations and identification of affected pathways.
About Cancer Genetics:
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see http://www.cancergenetics.com.
About BioDiscovery, Inc.
BioDiscovery is a leader in the development of breakthrough software and services for advanced copy number variation and expression analysis, enabling customers in drug discovery, research, and diagnostics by efficiently managing, integrating, and analyzing data generated using high-throughput microarray and next-generation sequencing technologies. For more information visit http://www.biodiscovery.com or call 310-414-8100310-414-8100.
Cancer Genetics contact information:
Investor Relations
Michael Rice
Life Science Advisors LLC
646-597-6979
Media Relations
RedChip Companies, Inc.
Paul Kuntz, 800-733-2447, ext. 105
paul(at)redchip(dot)com
BioDiscovery Inc. contact information:
Louis Culot
BioDiscovery
lculot(at)biodiscovery(dot)com
617-233-4921
Louis Culot, BIODISCOVERY, INC., http://www.biodiscovery.com, +1 (310) 414-8100, [email protected]
Share this article